Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Dublin, Ireland.
| Revenue (TTM) | $4.60B |
| Gross Profit (TTM) | $4.20B |
| EBITDA | $1.93B |
| Operating Margin | 26.90% |
| Return on Equity | 22.10% |
| Return on Assets | 6.86% |
| Revenue/Share (TTM) | $74.60 |
| Book Value | $74.10 |
| Price-to-Book | 3.25 |
| Price-to-Sales (TTM) | 3.36 |
| EV/Revenue | 3.876 |
| EV/EBITDA | 11.03 |
| Quarterly Earnings Growth (YoY) | 3.20% |
| Quarterly Revenue Growth (YoY) | 15.50% |
| Shares Outstanding | $64.92M |
| Float | $62.98M |
| % Insiders | 2.92% |
| % Institutions | 102.79% |
Volatility is currently contracting
Jazz Pharmaceuticals NASDAQ: JAZZ executives outlined the company's oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the Morgan Stanley Global Healthcare Conference.
Jazz Pharmaceuticals NASDAQ: JAZZ outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the expansion potential of HER2-targeted therapy Ziihera and ongoing lifecycle work for EPIDIOLEX. Get Jazz Pharmaceuticals alerts:Sign UpZiihera Data and Development Plans An unnamed Jazz executive said zanidatamab, marketed as Ziihera, produced a statistically significant overall-survival result for its zanidatamab-plus-chemotherapy arm versus a control arm in a second interim analysis.
Jazz Pharmaceuticals plc (JAZZ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript
Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsy Transaction strengthens Jazz's epilepsy pipeline and reinforces its commitment to advance treatment options in rare disease DUBLIN, Sept. 15, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. ("Actio") for $820 million upfront.
Jazz Pharmaceuticals plc (JAZZ) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs' reach.
DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 1:30 p.m.
Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.
HERIZON-GEA-01 results reinforce recently FDA-approved Ziihera as the definitive HER2-targeted backbone therapy in first-line GEA Longer follow up of Ziihera plus tislelizumab and chemotherapy shows improved OS hazard ratio, further supporting this regimen as the new standard of care Data submitted for presentation in fourth quarter 2026 For U.S. media and investors only DUBLIN, Aug. 31, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced second interim top-line overall survival (OS) results from the Phase 3 HERIZON-GEA-01 trial showing that Ziihera® (zanidatamab-hrii) in combination with chemotherapy demonstrated statistically significant and clinically meaningful improvements in OS compared with trastuzumab plus chemotherapy as first-line treatment for adults with HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The Ziihera plus chemotherapy OS hazard ratio improved compared with the first interim analysis.
DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The offering was upsized from the previously announced offering size of $1.0 billion aggregate principal amount of notes.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on JAZZ and any ticker you trade — then tracks every position and per-strategy win rate.
